Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

Lacerations Clinical Trial

Official title:

Multicenter, Prospective, Randomized Controlled Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Closure of Simple, Thoroughly Cleansed, Trauma-induced Wounds in the Emergency Department

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00547638
• Other study ID #: 07CS005
• Secondary ID: IDE Number:G0602
• Status: Completed
• Phase: Phase 2
• First received: October 17, 2007
• Last updated: August 2, 2013
• Start date: August 2007
• Est. completion date: March 2009

Study information

• Verified date: August 2013
• Source: Ethicon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, prospective, randomized controlled study for the purpose of comparing DERMABOND PROTAPE to DERMABOND HVD for closure of wounds in the Emergency Department. The objective of this study is to demonstrate whether the incidence of wound closure for DERMABOND PROTAPE is equivalent to that measured for DERMABOND HVD.

Description:

According to the literature, cyanoacrylate adhesives (topical skin adhesive) have performed as intended and have not produced results that would bring into question the safety or effectiveness of cyanoacrylate adhesive for closure of surgical incisions and traumatic wounds in humans.

As such, this is a multicenter, prospective, randomized controlled study for the purpose of comparing two forms of topical skin adhesives, DERMABOND PROTAPE & DERMABOND HVD for closure of wounds in the Emergency Department.

Patients presenting in the Emergency Department with traumatic wounds meeting the acceptance criteria will have their wounds closed with DERMABOND PROTAPE or DERMABOND HVD, and will be monitored and evaluated at 14 & 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• at least 1 year of age

• in good general health in the opinion of the Investigator.

• have at least one traumatic wound meeting the criteria for closure as defined in current Dermabond product labeling.

• patient must be willing to follow instructions for wound care listed in device labeling and refrain from picking at the device, applying topical medications to the wound, and swimming or soaking in a tub until the sutures are removed.

• patient agrees to return for follow-up evaluation

• patient (or guardian) signs the informed consent

• patient is reasonably expected to survive the study

Exclusion Criteria:

• significant multiple trauma (merely multiple wounds are allowed)

• peripheral vascular disease

• insulin dependent diabetes mellitus

• known to have a blood clotting disorder

• receiving antibiotic therapy for preexisting condition or infection

• known to be HIV-positive or otherwise immunocompromised

• known personal or family history of keloid formation or hypertrophy

• currently taking systemic steroids

• known allergy to cyanoacrylate, formaldehyde, tapes or adhesives

• participating in another current clinical study

• history of abnormal wound healing

• burst stellate lacerations due to a crush or hard blow

• animal or human bite or scratch

• decubitus ulcer

• puncture wound

• wound at mucocutaneous junction or in mucosal (but not excluding the vermillion border of the lip)

• wound on scalp covered by natural hair

• wound has visual evidence of active infection

• gangrenous wound

• wound requiring debridement of devitalized or contaminated tissue

• wound at site of active rash/skin lesion making evaluation difficult

• previously treated wound or has failed to heal

• wound in high skin tension area or across an area of increased skin tension, such as knuckles, elbows, or knees, unless the joint will be immobilized during the skin healing period or unless skin tension has been removed by application

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lacerations

Intervention

Device:
• cyanoacrylate with pressure sensitive mesh
Topical Skin Adhesive
• cyanoacrylate
Topical Skin Adhesive

Locations

Country	Name	City	State
United States	Duke University Health System	Durham	North Carolina
United States	Investigators Research Group, LLC	Indianapolis	Indiana
United States	Tulane Universtiy Hospital & Clinic	New Orleans	Louisiana
United States	Orlando Regional Healthcare System	Orlando	Florida
United States	Drexel University Hospital	Philadelphia	Pennsylvania
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	NextCare Institute For Clinical Research	Phoenix	Arizona
United States	Stony Brook University HSC	Stony Brook	New York
United States	Wake Forest University Baptist Medical Center	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The Comparison of Test and Control Arms Regarding Incidence of Clinical Infection at Day 14 and Day 30	Incidence of clinical infection (defined by observation of redness, swelling, purulent discharge, pain, increased skin temperature, fever or other systemic signs of injection) collected at the Day 14 and Day 30 visits. A formal statistical analysing using Fisher's Exact Test was performed.	Through Day 30	Yes
Other	The Incidence and Extent of Local Acute Inflammatory Reactions Including Edema, Erythema, Pain and Local Temperature at Day 14 and Day 30	Each parameter (edema, erythema, pain and location temperature) is measured on a 4 point scale (0, 1, 2, 3). The individual values are added to generate an overall AIRE Score. AIRE Scores were summarized as good (score=0) versus poor (score>0) by treatment group and compared for differences using the Fisher's Exact Test.	At Day 14 and Day 30	Yes
Other	Incidence of Skin Blistering at Day 14	The incidence of skin blistering is presented as a tabulation of the presence or absence of skin blistering by treatment group. A formal statistical analysis of the incidence of blistering at Day 14 was performed using the Fisher's Exact Test.	Day 14	Yes
Other	Incidence of Any Other Anticipated or Unanticipated Adverse Events	Adverse events were coded using the MedDRA dictionary. In addition severity, relationship to treatment and procedure, action taken and outcome were described. Adverse events were summarized by treatment group. No formal statistical analysis was performed on overall incidence of adverse events with the exception of clinical infection, acute inflammatory reactions and skin blistering.	Day 30	Yes
Primary	The Incidence of Wound Closure Post-treatment, as Defined by Continuous Approximation of Wound Margins From the Time of Wound Closure Until the Day of Evaluation Without Dehiscence or Need for Reclosure.	Data is presented as binomial tables of proportions of successes and failures for each treatment. The 90% two-sided exact confidence intervals (CI) for the differences in the proportions for each study group was calculated. The upper limit of the 90% CI was then taken to represent the upper limit of the one-sided 95% CI. The primary objective of the study was met if the upper limit of the one-sided 95% CI of the difference in proportions (comparator minus treatment) did not exceed 8%.	14 days (±2 days)	Yes
Secondary	Cosmesis	The evaluation of healing and cosmetic outcome post-treatment using the modified Hollander Cosmesis Scale (mHCS). The proportion of patients with a zero (0) score will be compared between the test and control arms.	30 days (±5 days)	No